1. Search Result
Search Result
Results for "

cyclic

" in MedChemExpress (MCE) Product Catalog:

540

Inhibitors & Agonists

3

Screening Libraries

3

Fluorescent Dye

19

Biochemical Assay Reagents

172

Peptides

1

Inhibitory Antibodies

120

Natural
Products

30

Recombinant Proteins

29

Isotope-Labeled Compounds

10

Antibodies

4

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Area
  • HY-P3193A

    Peptides Others
    Cyclic nona-L-arginine hydrochloride, a nonaarginine peptide used for drug delivery, translocates faster than their linear counterparts .
  • HY-P10235

    Amylin Receptor Neurological Disease
    Cyclic AC253 is an antagonist for amylin receptor, with IC50 of 0.3 μM. Cyclic AC253 exhibits neuroprotective efficacy against Aβ toxicity and abrogates Aβ-induced impairment of hippocampal long-term potentiation. Cyclic AC253 penetrate blood-brain barrier (BBB) .
  • HY-P1949A

    CXCR Cardiovascular Disease Cancer
    Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice .
  • HY-P0084

    SRIF-14; Somatostatin-14

    Peptides Cardiovascular Disease Neurological Disease
    Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
  • HY-P4102

    Peptides Cancer
    Cyclic PSAP peptide is a cyclic pentapeptide (DWLPK). Cyclic PSAP peptide exhibits agent-like properties and could inhibit metastatic spread and restrain tumor development in general in vivo .
  • HY-P3193

    Peptides Others
    Cyclic nona-L-arginine TFA, a nonaarginine peptide used for drug delivery, translocates faster than their linear counterparts .
  • HY-P10548

    Bacterial Infection
    Cyclic L27-11 is a cyclic peptide-like antibiotic with strong antibacterial activity against specific bacteria such as Pseudomonas sp. Cyclic L27-11 shows nanomolar antibacterial activity against Pseudomonas sp., especially Pseudomonas aeruginosa. Cyclic L27-11 interferes with the function of bacterial outer membrane protein LptD, preventing the normal transport of lipopolysaccharide (LPS), leading to the accumulation of membrane-like substances in bacterial cells, which in turn affects the survival of bacteria. Cyclic L27-11 can be used in the development of antibacterial agents .
  • HY-P0084R

    Peptides Cardiovascular Disease Neurological Disease
    Cyclic somatostatin (Standard) is the analytical standard of Cyclic somatostatin. This product is intended for research and analytical applications. Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
  • HY-P1949

    CXCR Cardiovascular Disease Cancer
    Cyclic MKEY is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice .
  • HY-P4100

    Somatostatin Receptor Others
    Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic Somatostatin Receptor SSTR agonist .
  • HY-P10793

    EGFR Apoptosis Cancer
    Cyclic(YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model .
  • HY-P10033

    Ser/Thr Protease Others
    SFTI-1 is a cyclic peptide trypsin inhibitor comprising 14 amino acid residues. SFTI-1 is a potent Bowman-Birk inhibitor.
  • HY-P10672

    Biochemical Assay Reagents Others
    SEI144 is a low nanomolar binder of USP15 and does not inhibit USP15 activity .
  • HY-P1789

    MMP Inflammation/Immunology Cancer
    CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM .
  • HY-P1789A

    MMP Inflammation/Immunology Cancer
    CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM .
  • HY-P10027

    Antibiotic Bacterial Infection
    Clovibactin is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
  • HY-P10027A

    Antibiotic Bacterial Infection
    Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
  • HY-P10835

    LAG-3 Cancer
    LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 + T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
  • HY-P1206

    Somatostatin Receptor Neurological Disease
    CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst1) with a Ki of 52 nM . CH 275 acts as a potent and selective sst1 agonist (IC50=30.9 nM) and also displays IC50 values of 345 nM, >1 μM, >10 μM, >10 μM for human sst3, sst4, sst2 and sst5, respectively . CH 275 can be used for the research of alzheimer’s disease .
  • HY-P10383A

    Peptides Infection
    SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .
  • HY-P10384A

    Peptides Infection
    SPSB2-iNOS inhibitory cyclic peptide-2 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-2 (HY-P10384). SPSB2-iNOS inhibitory cyclic peptide-2 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 TFA is reduction-resistant and oxidatively stable .
  • HY-P10383

    NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .
  • HY-P10385A

    Peptides Infection
    SPSB2-iNOS inhibitory cyclic peptide-3 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-3 (HY-P10385). SPSB2-iNOS inhibitory cyclic peptide-3 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 7 nM .
  • HY-P10384

    NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-2 (Compound CP2) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 is reduction-resistant and oxidatively stable .
  • HY-P5217

    Peptides Others
    CSTSMLKAC (peptide 2) is a cyclic 9 amino acid sequence that mimics endogenous peptide sequences. CSTSMLKAC homes to cardiomyocytes in the ischemic myocardium .
  • HY-P2202

    Bacterial Others
    Desferriferribactin is a cyclic peptide containing a thirteen-membered ring. Desferriferribactin is a precursor of pyoverdins .
  • HY-P5957

    Parasite Infection
    Omphalotin A is a cyclic peptide, and shows nematicidal activity .
  • HY-P3145

    Peptides Cancer
    Astin A is an antitumor cyclic pentapeptide. Astin A can be isolated from Aster tataricus .
  • HY-133801

    Peptides Others
    Unguisin A s a cyclic peptides that can be isolated from the marine-derived fungus Emericella unguis .
  • HY-125488

    Peptides Others
    Unguisin B s a cyclic peptides that can be isolated from the marine-derived fungus Emericella unguis .
  • HY-P10385

    Peptides Infection
    SPSB2-iNOS inhibitory cyclic peptide-3 (Compound CP3) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 7 nM .
  • HY-35028

    Amino Acid Derivatives Others
    Boc-Glu-Ofm is a peptide. Boc-Glu-Ofm has been used for the synthesis of ester insulin and cyclic peptide mixtures .
  • HY-P3557

    Adrenergic Receptor Cardiovascular Disease
    Mibenratide, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide can be used for heart failure research .
  • HY-P3557A

    Adrenergic Receptor Cardiovascular Disease
    Mibenratide TFA, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide TFA can be used for heart failure research .
  • HY-P1680

    Asterin

    Peptides Inflammation/Immunology Cancer
    Astin C (Asterin) is a cyclic pentapeptide with anticancer and anti-inflammatory properties .
  • HY-125357

    Peptides Metabolic Disease
    Ternatin (compound 2) is a cyclic heptapeptides that can be isolated from mushroom Coliorus versicolor. Ternatin inhibits fat-accumulation with an IC50 of 0.027 μM in 3T3-L1 adipocytes .
  • HY-P3929

    PKA Cancer
    PKI (14-24)amide is a potent PKA inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .
  • HY-P3929A

    PKA Cancer
    PKI (14-24)amide TFA is a potent PKA inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .
  • HY-W036160

    Amino Acid Derivatives Others
    N-Fmoc-O-ethyl-L-homoserine is an homoserine derivative, can be used in cyclic peptide compounds synthesis, as a reducing reagent .
  • HY-P10812

    Peptides Cancer
    CP61, a cyclic peptide, is a dual CtBP1/CtBP2 inhibitor. CP61 binds CtBP1 with 3 μM affinity. CP61 inhibits the heterodimerization and homodimerization of CtBP2 with an IC50 value of 19 μM. CP61 is promising for research of cancers .
  • HY-P10557

    Peptides Neurological Disease
    DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation .
  • HY-P2171

    Peptides Inflammation/Immunology
    CCP peptide is a synthetic cyclic citrullinated peptide (CCP) and used as the substrate for detecting anti-CCP antibodies serologically. CCP peptide functions as a target for autoantibodies with a very high specificity for rheumatoid arthritis (RA) .
  • HY-B1811
    Vasopressin
    Maximum Cited Publications
    12 Publications Verification

    Endogenous Metabolite Neurological Disease
    Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .
  • HY-P2171A

    Peptides Inflammation/Immunology
    CCP peptide TFA is a synthetic cyclic citrullinated peptide (CCP) and used as the substrate for detecting anti-CCP antibodies serologically. CCP peptide TFA functions as a target for autoantibodies with a very high specificity for rheumatoid arthritis (RA) .
  • HY-P3777

    Potassium Channel Neurological Disease
    β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents .
  • HY-P4012

    Vasopressin Receptor Endocrinology
    [Asu1,6-Arg8]Vasopressin is an vasopressin agonist which potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-releasing factor (CRF) in rat anterior pituitary cells in culture .
  • HY-P2698

    HDAC Apoptosis Cancer
    1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent HDAC inhibitor (IC50=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells .
  • HY-P10697

    LDLR Metabolic Disease
    VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
  • HY-P1178
    Cyclotraxin B
    3 Publications Verification

    Trk Receptor Neurological Disease
    Cyclotraxin B, a cyclic peptide, is a highly potent and selective TrkB inhibitor without altering the binding of BDNF. Cyclotraxin B non-competitively inhibits BDNF-induced TrkB activity with an IC50  of  0.30 nM. Cyclotraxin B can crosse the blood-brain-barrier and has analgesic and anxiolytic-like behavioral effects .
  • HY-P1178A

    Trk Receptor Neurological Disease
    Cyclotraxin B TFA, a cyclic peptide, is a highly potent and selective TrkB inhibitor without altering the binding of BDNF. Cyclotraxin B TFA non-competitively inhibits BDNF-induced TrkB activity with an IC50  of  0.30 nM. Cyclotraxin B TFA can crosse the blood-brain-barrier and has analgesic and anxiolytic-like behavioral effects .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: